|
|
Vaccine Detail
|
MF59/CpG ODN1826-adjuvanted MUC1-Maltose Binding Protein (MBP) Vaccine |
| Vaccine Information |
- Vaccine Name: MF59/CpG ODN1826-adjuvanted MUC1-Maltose Binding Protein (MBP) Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant fusion protein
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1; maltose binding protein (MBP) (Jie et al., 2022)
-
Adjuvant:
MF59/CpG ODN1826 (Jie et al., 2022)
- Immunization Route: subcutaneous injection
- Description: A recombinant fusion protein vaccine containing MUC1 tumor antigen (seven tandem repeats, 7×VNTR) fused to maltose binding protein (MBP), adjuvanted with MF59 oil-in-water emulsion and CpG ODN1826. Vaccination stimulates MUC1-specific humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. MF59 prolongs local retention of CpG 1826 and antigen in lymph nodes (>24h), enhances DC maturation by downregulating IL-6/STAT3, and promotes Th1 polarization. In preclinical studies, demonstrated significant tumor inhibition in B16-MUC1 melanoma with 80% survival at 70 days (prophylactic) and 60% at 50 days (therapeutic) vs. 30% with CpG alone. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various cancers including breast, prostate, and melanoma (Jie et al., 2022).
|
| Host Response |
|
|
| References |
Jie et al., 2022: Jie J, Liu G, Feng J, Huo D, Wu Y, Yuan H, Tai G, Ni W. MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3. International journal of molecular sciences. 2022; 23(18); . [PubMed: 36142800].
|
|
